TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and$69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand f ...